The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations ; volume:18 ; number:1 ; day:11 ; month:12 ; year:2018 ; pages:1-6 ; date:12.2018
BMC cancer ; 18, Heft 1 (11.12.2018), 1-6, 12.2018
- Creator
-
Yoshimura, Akihiro
Yamada, Tadaaki
Okura, Naoko
Takeda, Takayuki
Furutani, Wataru
Kubota, Yutaka
Shiotsu, Shinsuke
Hiranuma, Osamu
Nishioka, Naoya
Chihara, Yusuke
Tamiya, Nobuyo
Kaneko, Yoshiko
Uchino, Junji
Takayama, Koichi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-5153-4
- URN
-
urn:nbn:de:101:1-2019012713173579147637
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yoshimura, Akihiro
- Yamada, Tadaaki
- Okura, Naoko
- Takeda, Takayuki
- Furutani, Wataru
- Kubota, Yutaka
- Shiotsu, Shinsuke
- Hiranuma, Osamu
- Nishioka, Naoya
- Chihara, Yusuke
- Tamiya, Nobuyo
- Kaneko, Yoshiko
- Uchino, Junji
- Takayama, Koichi
- SpringerLink (Online service)
Other Objects (12)
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
The Role of EGFR
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
EGFR-TKIs resistance via EGFR-independent signaling pathways
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR -TKIs plus Bevacizumab: A Case Report
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
The Role of EGFR
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
EGFR-TKIs resistance via EGFR-independent signaling pathways
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR -TKIs plus Bevacizumab: A Case Report
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
The Role of EGFR
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
EGFR-TKIs resistance via EGFR-independent signaling pathways
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations